@charlesarthur@R_H_Ebright@Laurie_Garrett Dutch district court ruled that the government was right to ask Fouchier to obtain an export license before sending two hotly debated papers out for publication. The ruling, published yesterday (Dutch), could provide new roadblocks for Fouchier's research in the future.
@charlesarthur@R_H_Ebright@Laurie_Garrett which was published in Science in June 2012. The fight also involved an accompanying paper published in the same issue in which Fouchier and others tried to gauge the likelihood that such viruses arise spontaneously in nature.
@charlesarthur@R_H_Ebright@Laurie_Garrett The Dutch required Fouchier to formally ask official permission first, interpreted E.U. regulations aimed at preventing the proliferation of weapons of mass destruction and so-called "dual use" technology that could be used for good or evil, the court in Haarlem said. #whyworry
@charlesarthur@R_H_Ebright@Laurie_Garrett The decision means that future H5N1 transmissibility studies—which Fouchier resumed after a worldwide moratorium ended in January—would require an official stamp of approval as well. The same could be true for similar studies involving H7N9, a strain that emerged in China
@charlesarthur@R_H_Ebright@Laurie_Garrett The same could be true for similar studies involving H7N9, a strain that emerged in China this spring, because the government could consider any studies that give the virus new capabilities as providing dual use findings.
@charlesarthur@R_H_Ebright@Laurie_Garrett Fouchier was unavailable for comment today, but he has said in previous interviews that the Dutch government is infringing on academic freedom and putting him and other scientists in the Netherlands at an unfair disadvantage compared to scientists from other countries. 😳
@charlesarthur@R_H_Ebright@Laurie_Garrett Fouchier's H5N1 work triggered a worldwide furor in late 2011, along with a similar study by Yoshihiro Kawaoka of the University of Wisconsin, Madison, and the University of Tokyo, when the U.S. National Science Advisory Board for Biosecurity (NSABB) judged that it should not be
@charlesarthur@R_H_Ebright@Laurie_Garrett published without striking the most sensitive details. In the wrong hands, the NSABB reasoned, the studies could be used to turn H5N1 into a bioweapon. The board reversed that decision in March 2012 and gave the papers a green light.
@charlesarthur@R_H_Ebright@Laurie_Garrett But while the Kawaoka paper was published online in Nature in early May 2012 Fouchier's study was held up longer because of the Dutch government's position. #Fouchier applied for export license under protest and received it on 27 April 2012 allowing the paper finally 2b published
@charlesarthur@R_H_Ebright@Laurie_Garrett But Erasmus MC also filed appeal against the government's decision; when the government rejected it it took the issue to the district court
The government based its decision on EU regulations issued 2009 that aim to prevent the spread of nuclear, chemical and biological weapons🧐
@charlesarthur@R_H_Ebright@Laurie_Garrett Those rules put limits on the export, trade, and transfer of a range of materials, including dangerous flu viruses, and also apply to technical know-how that could be used to make such weapons.
@charlesarthur@R_H_Ebright@Laurie_Garrett Erasmus MC and Fouchier argued that the rules don't apply to Fouchier's papers because an Annex to the document carves out exceptions for ″basic scientific research″ and for information already ″in the public domain.″
@charlesarthur@R_H_Ebright@Laurie_Garrett The ferret studies were basic scientific research Fouchier's lawyer argued because the researchers sought to better understand mammalian transmissibility of an influenza strain; meanwhile methods used in the study to generate mutants had been described before and were well-known.
@charlesarthur@R_H_Ebright@Laurie_Garrett The court which heard arguments in the case on 29 Aug did not buy this line of reasoning Making H5N1 airborne was not just basic research but was a "practical goal," the judges said;
@charlesarthur@R_H_Ebright@Laurie_Garrett while the methods had been described before, the researchers had "taken steps and made choices that have led to entirely new outcomes."
@charlesarthur@R_H_Ebright@Laurie_Garrett To avoid hollowing out the regulations, any exceptions "should be interpreted strictly," the court said, adding that it's not up to individual researchers to decide whether their work is basic research.
@charlesarthur@R_H_Ebright@Laurie_Garrett The court acknowledged that its decision could cause delays in the dissemination of scientific information but said this "disadvantage" is outweighed by the importance of preventing proliferation.Fouchier #ErasmusMC have 6 weeks to take their case to Court of Appeal in Amsterdam
• • •
Missing some Tweet in this thread? You can try to
force a refresh
What was really #wewanttheminfected
And use #schools as a tap for controlled spread. No transparency, no testing no mask
Lets spread the lie that mask simply don’t work
Begin
Here #polarisation starts driven by misinformation and intransparancy by your government. Everybody could see that the measures were nog in line with urgency.
What were they hiding? Why no #zerorisk#zerocovid with borders closed. It could be done
2020: wait we know this will
Lead to many many deaths but the #vaccin is almost here, working hard, we know the #SPIKE is a big thing, hold on #Hopium being built.
Meanwhile lets keep up the lie of children not important to monitor😢 we know from SARS they build less #antibodies lets presume they just not
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults - ScienceDirect sciencedirect.com/science/articl…
In the Moderna trial, the excess risk of serious AESIs 15.1 per 10k participants was higher than the risk reduction for COVID-19 hospitalization relative to the placebo group (6.4 per 10,000 participants). [3] In the Pfizer trial, the excess risk of serious AESIs 10.1 per 10K was
higher than the risk reduction for COVID-19 hospitalization relative to the placebo group (2.3 per 10,000 participants).